Aggregated α-synuclein and complex I deficiency: exploration of their relationship in differentiated neurons

alpha-Synuclein becomes misfolded and aggregated upon damage by various factors, for example, by reactive oxygen species. These aggregated forms have been proposed to have differential toxicities and their interaction with mitochondria may cause dysfunction within this organelle that contributes to the pathogenesis of Parkinson's disease (PD). In particular, the association of a-synuclein with mitochondria occurs through interaction with mitochondrial complex I and importantly defects of this protein have been linked to the pathogenesis of PD. Therefore, we investigated the relationship between aggregated alpha-synuclein and mitochondrial dysfunction, and the consequences of this interaction on cell survival. To do this, we studied the effects of alpha-synuclein on cybrid cell lines harbouring mutations in either mitochondrial complex I or IV. We found that aggregated alpha-synuclein inhibited mitochondrial complex I in control and complex IV-deficient cells. However, when aggregated alpha-synuclein was applied to complex I-deficient cells, there was no additional inhibition of mitochondrial function or increase in cell death. This would suggest that as complex I-deficient cells have already adapted to their mitochondrial defect, the subsequent toxic effects of alpha-synuclein are reduced.